We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

40 hedge funds and large institutions have $289M invested in Heron Therapeutics in 2014 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,700% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 1

2,646% more capital invested

Capital invested by funds: $10.5M → $289M (+$279M)

1,233% more funds holding

Funds holding: 3 → 40 (+37)

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
40
Holders Change
+37
Holders Change %
+1,233.33%
% of All Funds
1.16%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.17%
New
38
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$58.9M
2
Franklin Resources
Franklin Resources
California
+$43.4M
3
BC
Broadfin Capital
New York
+$29.8M
4
BBA
Baker Bros. Advisors
New York
+$29M
5
SC
Savitr Capital
California
+$24.8M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$445K
2
VM
VHCP Management
New York
-$13
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$61.3M +$58.9M +4,408,987 New
Franklin Resources
2
Franklin Resources
California
$45.2M +$43.4M +3,251,353 New
BC
3
Broadfin Capital
New York
$31.1M +$29.8M +2,233,173 New
BBA
4
Baker Bros. Advisors
New York
$30.2M +$29M +2,167,784 New
SC
5
Savitr Capital
California
$25.8M +$24.8M +1,856,761 New
PA
6
Perceptive Advisors
New York
$24.5M +$23.5M +1,762,426 New
VM
7
VHCP Management
New York
$15.2M -$13 -1 -0%
DCM
8
Driehaus Capital Management
Illinois
$12.9M +$12.3M +924,231 New
TCM
9
Tekla Capital Management
Massachusetts
$9.69M +$9.31M +696,597 New
Fidelity Investments
10
Fidelity Investments
Massachusetts
$6.79M +$6.52M +487,820 New
KCM
11
Kingdon Capital Management
New York
$5.18M +$4.99M +373,315 New
ICM
12
ISZO Capital Management
New York
$4.83M +$4.64M +347,051 New
TAM
13
THB Asset Management
Connecticut
$2.53M +$2.43M +181,945 New
Millennium Management
14
Millennium Management
New York
$2.4M +$2.31M +172,697 New
GP
15
GLG Partners
United Kingdom
$1.75M +$1.69M +126,182 New
AC
16
Ascend Capital
California
$1.75M +$1.68M +125,663 New
Morgan Stanley
17
Morgan Stanley
New York
$1.62M +$1.56M +116,761 New
FM
18
Forward Management
California
$1.13M +$1.24M +93,014 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$865K +$832K +62,243 New
MCP
20
Moab Capital Partners
New York
$775K +$745K +55,734 New
U
21
UBS
Switzerland
$726K +$697K +52,176 New
Jane Street
22
Jane Street
New York
$622K +$598K +44,760 New
EEG
23
E.E. Geduld
$348K – – –
Tudor Investment Corp
24
Tudor Investment Corp
Connecticut
$348K +$334K +24,999 New
Northern Trust
25
Northern Trust
Illinois
$298K +$287K +21,453 New
1
2

HRTX Hedge Fund Activity: Q1 2014 in Review

40 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2014, worth a combined $289M — up 2,646% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new HRTX positions and 1 closed out — a net gain of 37 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $58.9M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $445K sold.

  • 40 institutional investors held Heron Therapeutics (HRTX) as of Q1 2014, up from 3 in Q4 2013.
  • Funds reported $289M of Heron Therapeutics stock for Q1 2014, up 2,646% quarter-over-quarter.
  • 38 funds opened new Heron Therapeutics positions in Q1 2014 and 1 closed out, a net change of +37 holders.
  • The largest Heron Therapeutics buyer in Q1 2014 was Tang Capital Management, an estimated $58.9M added.
  • The largest Heron Therapeutics seller in Q1 2014 was Alyeska Investment Group, an estimated $445K sold.

Based on aggregated 13F filings for Q1 2014.